Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China

Whitehawk Therapeutics, Inc.

EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.
Aadi disputes EOC's allegations of material breach; believes termination is for convenience.
Aadi had received $14M upfront and $1M milestone; lost potential $257M in milestones and royalties.
No further payments from EOC expected; Aadi loses exclusive development/commercialization partner for China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.